



Monsenso signs new agreement with a leading pharmaceutical for a real-world data project in Denmark

1.11.2023 15:15:41 CET | Monsenso | Company Announcement

Monsenso signs a new agreement with a leading pharmaceutical company to implement its solution for decentralised patient-centric real-world data collection in a chronic disease area.

Company announcement no. 15-2023

Copenhagen, 2023.11.01

(This message includes inside information)

Under the new agreement, Monsenso will deliver and support real-world patient data collection for a decentralised patient-centric study expected to take place over the next 12 months.

The agreement and the solution delivered build on Monsenso's existing platform, which will be customised to support the specific study and the disease of the patient group. It also includes developing new features to support the patient-centric real-world data study, which will position Monsenso's solution even stronger in the future.

"With this project, we hope to contribute to getting deeper learnings on which treatments work for which patients by continuously engaging and collecting real-world data from patients.

The potential of this engagement is significant - both with the pharmaceutical company itself across other geographies and disease areas as well as with similar companies." says Thomas Lethenborg, CEO of Monsenso.

The project comes one year into the start of the PhaseV research project, where Monsenso further develops its solution to fully support decentralised real-world data studies and trials in collaboration with leading pharmaceutical companies and research institutions.

The agreement is not expected to impact Monsenso's revenue projections for 2023, but it is expected to contribute to the growth in the coming years.

Further information:

Monsenso:

CEO

Thomas Lethenborg

Tel. +45 21 29 88 27

E-mail: lethenborg@monsenso.com

Certified Adviser:

Norden CEF A/S

John Norden

Tel. +45 20 72 02 00

E-mail: jn@nordencef.dk

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit

www.monsenso.com

Attachments

- [Download announcement as PDF.pdf](#)
- [Patient with smartphone.jpg](#)
- [Clinician with clinical web portal.jpg](#)